Contents

Search


nebivolol (Bystolic)

Tradename: Bystolic. FDA approved 2007 Indications: - hypertension - angina pectoris [2] - chronic heart failure - rate control in atrial fibrillation - secondary prevention in patients with cardiovascular disease [2] Adverse effects: - headache - fatigue - dizziness - diarrhea Mechanism of action: - beta-1 adrenergic receptor antagonist - vasodilating effects

Interactions

drug adverse effects of beta-adrenergic receptor antagonists

General

beta-1 adrenergic receptor antagonist (beta-1 blocker)

References

  1. Weiss RJ et al, A randomized, double-blind, placebo-controlled parallel group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension J Clin Hypertens 2007, 9:667 PMID: 17786067
  2. Deprecated Reference